Full Text View
Tabular View
Study Results
Related Studies
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
This study has been completed.
Study NCT00029107   Information provided by National Institutes of Health Clinical Center (CC)

First Received on January 5, 2002.   Last Updated on April 10, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C
Vasculitis
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
More general conditions related to this trial
Cardiovascular Diseases
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Vascular Diseases
Virus Diseases
Interventions listed in this trial
Rituximab
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services